FSSAI Flags Nestlé Over ‘5 HMOs’ in Infant Formula

Nestlé India is facing three separate adjudication cases filed by the Food Safety and Standards Authority of India (FSSAI) over alleged violations in its infant nutrition products, specifically NAN Excella Pro Stage 1 and Lactogen Pro 1, reported several media outlets including CNBCTV18. The regulator flagged promotional claims such as “5 HMOs” and “easy-to-digest whey,” and also found a follow-up formula sample non-compliant with prescribed biotin levels.

The company is facing three cases because of the way it promoted its baby food products. Claims like “5 HMOs” and “easy‑to‑digest whey” on packs of NAN Excella Pro Stage 1 and Lactogen Pro 1 have been flagged. One of its follow‑up formulas was also found to have less biotin than required.

HMOs, or Human Milk Oligosaccharides, are special complex sugars found naturally in human breast milk. They are the third most abundant solid component after lactose and fat, and while babies cannot digest them directly, HMOs play a crucial role in building immunity, gut health, and overall development.

For Indian parents, HMOs are being marketed as a “closer-to-breast-milk” innovation in baby food. But regulators like FSSAI are cautious about how these claims are presented, since marketing cannot mislead families into thinking formula equals breast milk.

What FSSAI Found & Regulatory Action

• Products under scrutiny:
  NAN Excella Pro Stage 1 – flagged for claims about “5 HMOs” and “Whey Protein”.
  Lactogen Pro 1 – flagged for claim that its whey protein is “easy to digest”.
• Follow-up formula issue:
  A Nestlé infant formula was found sub-standard in biotin content during lab analysis, confirmed again by referral testing.
• Legal basis:
  Regulation 4(2), Foods for Infant Nutrition Regulations, 2020 – restricts promotional claims intended to boost sales.
  Section 3, IMS Act, 1992 – prohibits advertising and promotion of infant milk substitutes and related products.

Nestlé India’s Response

• Products are fully compliant with applicable regulations.
• Labels were approved by FSSAI’s expert committee.
• Company submitted a detailed response citing scientific literature to support its claims.

What This Means

Issue	Details	Regulatory Concern
Promotional Claims	“5 HMOs” & “easy-to-digest whey”	Misleading marketing, contravenes infant food rules
Biotin Deficiency	Follow-up formula below prescribed biotin levels	Nutritional compliance failure
Legal Cases	3 adjudication cases filed	Could lead to penalties, stricter oversight
Corporate Response	Claims backed by scientific literature	Dispute over interpretation of regulations

Trade-offs

• Consumer Trust:
  Promotional claims may mislead parents, undermining confidence in infant nutrition products.
• Regulatory Precedent:
  This case could set stricter enforcement standards for baby food marketing in India.
• Market Impact:
  Nestlé’s shares already dipped following the announcement, reflecting investor concerns.

Editorial Takeaway

This action highlights India’s tightening scrutiny of infant nutrition marketing, especially around health-related claims. For parents, the key takeaway is that regulators are prioritizing transparency and compliance over promotional messaging. For Nestlé, the challenge lies in balancing scientific substantiation with regulatory restrictions that prohibit promotional claims in this sensitive category.

FSSAI is making sure baby food companies don’t mislead parents with fancy claims. Nestlé now has to prove its products are safe and its labels are correct.